Martingale Asset Management L P grew its holdings in Gossamer Bio, Inc. (NASDAQ:GOSS – Get Rating) by 39.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,027 shares of the company’s stock after buying an additional 14,215 shares during the quarter. Martingale Asset Management L P owned 0.06% of Gossamer Bio worth $420,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Denali Advisors LLC purchased a new stake in shares of Gossamer Bio in the second quarter valued at approximately $75,000. DekaBank Deutsche Girozentrale increased its position in shares of Gossamer Bio by 10.1% in the first quarter. DekaBank Deutsche Girozentrale now owns 16,300 shares of the company’s stock valued at $145,000 after buying an additional 1,500 shares in the last quarter. Amalgamated Bank purchased a new stake in shares of Gossamer Bio in the first quarter valued at approximately $65,000. Allspring Global Investments Holdings LLC increased its position in shares of Gossamer Bio by 67.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 27,110 shares of the company’s stock valued at $226,000 after buying an additional 10,908 shares in the last quarter. Finally, Walleye Capital LLC boosted its stake in shares of Gossamer Bio by 39.2% in the first quarter. Walleye Capital LLC now owns 252,825 shares of the company’s stock worth $2,195,000 after acquiring an additional 71,201 shares during the last quarter. 67.57% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the company. Barclays lifted their price target on Gossamer Bio from $12.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 17th. Wedbush started coverage on Gossamer Bio in a research note on Monday, September 19th. They issued an “outperform” rating and a $24.00 price target on the stock. Raymond James lowered their price objective on Gossamer Bio from $18.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, November 17th. JPMorgan Chase & Co. began coverage on Gossamer Bio in a research report on Wednesday, September 21st. They issued a “neutral” rating and a $17.00 target price on the stock. Finally, The Goldman Sachs Group began coverage on Gossamer Bio in a research report on Thursday, October 20th. They issued a “buy” rating and a $22.00 target price on the stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.30.
Insiders Place Their Bets
Gossamer Bio Price Performance
Shares of NASDAQ GOSS opened at $9.04 on Wednesday. The stock’s 50-day moving average is $11.53 and its two-hundred day moving average is $10.64. The company has a debt-to-equity ratio of 3.73, a current ratio of 5.93 and a quick ratio of 5.93. Gossamer Bio, Inc. has a 1-year low of $5.64 and a 1-year high of $15.19. The company has a market cap of $854.07 million, a price-to-earnings ratio of -3.13 and a beta of 0.88.
Gossamer Bio (NASDAQ:GOSS – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.01. Analysts forecast that Gossamer Bio, Inc. will post -2.75 EPS for the current fiscal year.
About Gossamer Bio
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.
- Get a free copy of the StockNews.com research report on Gossamer Bio (GOSS)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.